Details:

Personal Author:
Jereb, John A. ; Goldberg, Stefan V. ; Powell, Krista. ; Villarino, M. Elsa. ; Lobue, Philip. ;
Jereb, John A. ; Goldberg, Stefan V. ; Powell, Krista. ; Villarino, M. Elsa. ; Lobue, Philip. ; Less -
Corporate Authors:
National Center for HIV, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination. ;
Description:
Preventing tuberculosis (TB) by treating latent Mycobacterium tuberculosis infection (LTBI) is a cornerstone of the U.S. strategy for TB elimination (1,2). Three randomized controlled trials have shown that a new combination regimen of isoniazid (INH) and rifapentine (RPT) administered weekly for 12 weeks as directly observed therapy (DOT) is as effective for preventing TB as other regimens and is more likely to be completed than the U.S. standard regimen of 9 months of INH daily without DOT (2–5). This report provides CDC recommendations for using the INH-RPT regimen. The new regimen is recommended as an equal alternative to the 9-month INH regimen for otherwise healthy patients aged ≥12 years who have LTBI and factors that are predictive of TB developing (e.g., recent exposure to contagious TB). The new regimen also can be considered for other categories of patients when it offers practical advantages. Although the INH-RPT regimen was well tolerated in treatment trials, monitoring for adverse effects is recommended. Severe adverse effects should be reported to the Food and Drug Administration (FDA) and CDC. Reported by John A. Jereb, MD, Stefan V. Goldberg, MD, Krista Powell, MD, M. Elsa Villarino, MD, Philip LoBue, MD, Div of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention.
Subject:
[+]
Adult
Antitubercular Agents/administration & Dosage
Antitubercular Agents/contraindications
Child
Child, Preschool
Directly Observed Therapy
Drug Administration Schedule
Drug Therapy, Combination
Evidence-Based Medicine
Humans
Isoniazid/administration & Dosage
Isoniazid/contraindications
Latent Tuberculosis/drug Therapy
Randomized Controlled Trials As Topic
Rifampin/administration & Dosage
Rifampin/analogs & Derivatives
Rifampin/contraindications

Document Type:
Journal Article ;
Genre:
Practice Guideline ;
Place as Subject:
United States ;
Collection(s):
Guidelines and Recommendations
Main Document Checksum:
[+]
urn:sha256:e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855
File Type:

Supporting Files

• No Additional Files

More +